Sanwa Kagaku Kenkyusho Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sanwa Kagaku Kenkyusho Co., Ltd.
David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.
Following Amneal’s first biosimilar launch last month, the company has made it two with the introduction of its Releuko version of filgrastim in the US. It plans to complete the trinity with its Fylnetra pegfilgrastim biosimilar early next year.
Fresh from introducing its first biosimilar in the US, Amneal expects two additional biosimilars to launch in the next couple of months as well as several further generics by year end. The firm also has its eye on future biosimilars opportunities where it can be early to market.
Plus deals involving Dong-A/Polifarma, Intas/Syna, Kissei/Synmosa, Ono/Memo, Takeda/Shionogi, Fosun/Lilly and JW Therapeutics/2seventy bio.
- Drug Delivery
- Generic Drugs
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools